Published in Gene Therapy Weekly, March 24th, 2005
The NEJM article, "Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage," presents the results of the largest clinical trial ever conducted with a pharmacologic agent for the treatment of ICH. The study found a reduction in hematoma growth (bleeding in the brain), decreased mortality, and improvement in neurological and clinical outcomes in patients treated with NovoSeven compared to placebo.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.